This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción RDUS
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
Competidores de Radius Health, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.10 |
| 52 Week High | US$23.00 |
| 52 Week Low | US$4.97 |
| Beta | 0.52 |
| 1 Month Change | -0.39% |
| 3 Month Change | 78.76% |
| 1 Year Change | -27.08% |
| 3 Year Change | -55.21% |
| 5 Year Change | -71.49% |
| Change since IPO | 26.09% |
Noticias y actualizaciones recientes
Recent updates
Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype
Aug 11Reevaluating Radius Health
Feb 24Radius Health EPS misses by $0.02, misses on revenue
May 07When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?
Feb 23
Revisiting Radius Health
Feb 01Radius Health acquires global rights to RAD011 in Prader-Willi syndrome
Jan 06How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?
Jan 01
Radius Health on-track for record quarterly revenue for TYMLOS-SC
Dec 15Rentabilidad de los accionistas
| RDUS | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | -0.1% | 2.7% | 0.3% |
| 1Y | -27.1% | 2.9% | 24.2% |
Rentabilidad vs. Industria: RDUS underperformed the US Biotechs industry which returned -22.1% over the past year.
Rentabilidad vs. Mercado: RDUS underperformed the US Market which returned -11.6% over the past year.
Volatilidad de los precios
| RDUS volatility | |
|---|---|
| RDUS Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: RDUS's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: RDUS's weekly volatility (10%) has been stable over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2003 | 293 | G. Martin | radiuspharm.com |
Resumen de fundamentos de Radius Health, Inc.
| Estadísticas fundamentales de RDUS | |
|---|---|
| Capitalización bursátil | US$480.77m |
| Beneficios(TTM) | -US$68.63m |
| Ingresos (TTM) | US$223.36m |
2.2x
Ratio precio-ventas (PS)-7.0x
Ratio precio-beneficio (PE)¿Está RDUS sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de RDUS | |
|---|---|
| Ingresos | US$223.36m |
| Coste de los ingresos | US$19.47m |
| Beneficio bruto | US$203.89m |
| Otros gastos | US$272.52m |
| Beneficios | -US$68.63m |
Últimos beneficios comunicados
Jun 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.44 |
| Margen bruto | 91.28% |
| Margen de beneficio neto | -30.72% |
| Ratio deuda/patrimonio | -124.2% |
¿Cómo se ha desempeñado RDUS a largo plazo?
Ver rendimiento histórico y comparativa